Liraglutide + empagliflozin

Liraglutide + empagliflozin has been studied in 2 papers since 2026: 2 observational studies in people; 2 in the past year. The newest paper, Oct 26, 2026: “Cardiovascular and economic outcomes of combined liraglutide and empagliflozin therapy in type 2 diabetes: a 6-year study”.

Intervention

2 papers study it31 more mention it5 findingsUpdated

PubChemPubChemChEBIChEBI

8 new papers in 30 daysSee all 33 papers on liraglutide + empagliflozin

At a glance

The findings reach people, from one lab or study. 1 lab in 1 country.

“The combination group displayed the lowest risk for developing the composite outcome of non-fatal cardiovascular events after adjusting for age, sex, hypertension, hyperlipidemia, smoking and CAD”
Cardiovascular and economic outcomes of combined liraglutide and empagliflozin therapy in type 2 diabetes: a 6-year studyESC Congress 2026 abstract2026doi:10.1093/eurheartj/ehag785.4186

None of its findings points the other way.

Humans: a single group. Cells, worms or flies and mice: nothing yet.
  • 1 lab in 1 country
  • Humans2

What did studies of liraglutide + empagliflozin find?

1

Studies of liraglutide + empagliflozin measured one outcome, Cost per patient per month.

Cost per patient per month

downin humans1

1 study
  1. Liraglutide + empagliflozin is linked with lower cost per patient per month in humans (cost of treatment plus cost of hospitalization for non-fatal cardiovascular events) (combination 133 € (95%CI 0-266) vs insulin 562 € (95%CI 344-781)).

    Humanscost of treatment plus cost of hospitalization for non-fatal cardiovascular eventsthrough 80 months

What is liraglutide + empagliflozin linked with?

4

Studies link liraglutide + empagliflozin with 4 measures, among them heart failure hospitalization, non-fatal cardiovascular events and amyloid β1−40.

Heart failure hospitalization

downin humans1

1 study
  1. Liraglutide + empagliflozin is linked with a lower risk of heart failure hospitalization in humans (compared with insulin, GLP1-RA and SGLT2i groups).

    Humanscompared with insulin, GLP1-RA and SGLT2i groupsmedian follow-up 69 months

More on Heart failure hospitalization

Non-fatal cardiovascular events

downin humans1HR 4.36

1 study
  1. Liraglutide + empagliflozin is linked with a lower risk of non-fatal cardiovascular events in humans (HR=4.36, 95%CI 2.04-9.33 (insulin vs combination); HR=2.45 for GLP1-RA and HR=3.07 for SGLT2i vs combination).

    Humansadjusted for age, sex, hypertension, hyperlipidemia, smoking and CAD; effect shown as insulin vs combination HRmedian follow-up 69 months

More on Non-fatal cardiovascular events

Amyloid β1−40

downin humans1

1 study
  1. Liraglutide + empagliflozin is associated with amyloid β1−40 in humans (Metformin-treated type 2 diabetes; compared with insulin) (-50.7% versus -30.7% with insulin).

    HumansMetformin-treated type 2 diabetes; compared with insulinplasma12 monthsn = 183

More on Amyloid β1−40

Carotid intima-media thickness

downin humans1

1 study
  1. Liraglutide + empagliflozin is associated with carotid intima-media thickness in humans (Metformin-treated type 2 diabetes; compared with insulin) (-10.7% versus -1.7% with insulin).

    HumansMetformin-treated type 2 diabetes; compared with insulincarotid artery12 monthsn = 183

More on Carotid intima-media thickness

Latest

Dec 2025: 1Jan 2026: 2Feb 2026: 3Mar 2026: 3Apr 2026: 0May 2026: 0Jun 2026: 1Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 4Nov 2026: 418 papers in 12 months
AHA Scientific Sessions 2026 Abstract

Amputations differ by drug in type 2 diabetes with leg artery disease

Among adults with type 2 diabetes and leg artery disease, one-year minor amputation rates were 1.0% for drugs such as semaglutide versus 1.6% for drugs such as…Among adults with type 2 diabetes and leg artery disease, one-year minor amputation rates were 1.0% for drugs such as semaglutide versus 1.6% for drugs such as empagliflozin.

Cohort studyType 2 diabetes

See all 33 papers on liraglutide + empagliflozin